[go: up one dir, main page]

MX2017010304A - Composiciones farmaceuticas que comprenden meloxicam. - Google Patents

Composiciones farmaceuticas que comprenden meloxicam.

Info

Publication number
MX2017010304A
MX2017010304A MX2017010304A MX2017010304A MX2017010304A MX 2017010304 A MX2017010304 A MX 2017010304A MX 2017010304 A MX2017010304 A MX 2017010304A MX 2017010304 A MX2017010304 A MX 2017010304A MX 2017010304 A MX2017010304 A MX 2017010304A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
meloxicam
include meloxicam
compositions
nsaid
Prior art date
Application number
MX2017010304A
Other languages
English (en)
Other versions
MX380762B (es
Inventor
Tabuteau Herriot
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60389519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017010304(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of MX2017010304A publication Critical patent/MX2017010304A/es
Publication of MX380762B publication Critical patent/MX380762B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

En la presente se describen composiciones que comprenden un AINE, tal como meloxicam en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones se pueden administrar por vía oral, por ejemplo, para mejorar la biodisponibilidad o farmacocinética del AINE para el tratamiento de afecciones, tales como el dolor.
MX2017010304A 2015-11-25 2016-04-11 Composiciones farmacéuticas que comprenden meloxicam. MX380762B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259993P 2015-11-25 2015-11-25
PCT/US2016/026991 WO2016131067A2 (en) 2015-02-10 2016-04-11 Pharmaceutical compositions comprising meloxicam

Publications (2)

Publication Number Publication Date
MX2017010304A true MX2017010304A (es) 2018-06-19
MX380762B MX380762B (es) 2025-03-12

Family

ID=60389519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010304A MX380762B (es) 2015-11-25 2016-04-11 Composiciones farmacéuticas que comprenden meloxicam.
MX2021003230A MX2021003230A (es) 2015-11-25 2017-08-09 Composiciones farmaceuticas que comprenden meloxicam.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003230A MX2021003230A (es) 2015-11-25 2017-08-09 Composiciones farmaceuticas que comprenden meloxicam.

Country Status (22)

Country Link
EP (3) EP4008319B1 (es)
JP (6) JP6746612B2 (es)
KR (9) KR102465027B1 (es)
CN (2) CN113144218A (es)
AU (4) AU2016218992C1 (es)
CA (3) CA3204396C (es)
CY (1) CY1125193T1 (es)
DK (1) DK3256138T3 (es)
ES (1) ES2913288T3 (es)
HU (1) HUE058677T2 (es)
IL (3) IL281863B2 (es)
LT (1) LT3256138T (es)
MX (2) MX380762B (es)
MY (1) MY191574A (es)
NZ (2) NZ742220A (es)
PL (1) PL3256138T3 (es)
PT (1) PT3256138T (es)
RS (1) RS63260B1 (es)
SG (2) SG10202010157VA (es)
SI (1) SI3256138T1 (es)
SM (1) SMT202200194T1 (es)
WO (1) WO2016131067A2 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US9821075B2 (en) 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR102465027B1 (ko) * 2015-02-10 2022-11-09 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12485176B2 (en) 2015-02-10 2025-12-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
NZ796097A (en) 2017-01-04 2025-07-25 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
EP4650374A2 (en) * 2017-05-10 2025-11-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
CA3105476A1 (en) * 2018-07-03 2020-01-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN112839635A (zh) 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂
US20230285306A1 (en) * 2018-09-28 2023-09-14 Axsome Therapeutics, Inc. Dosage forms comprising active pharmaceutical ingredients
EP3920909A4 (en) * 2019-02-06 2022-11-30 Axsome Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM
CN114555082B (zh) * 2019-07-26 2024-08-16 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的稳定的药剂学组合物
US20240058354A1 (en) 2020-04-06 2024-02-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US12128052B2 (en) 2020-05-28 2024-10-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US20250352478A1 (en) * 2020-11-06 2025-11-20 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
AU2021375409A1 (en) * 2020-11-06 2023-06-29 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
US20250352552A1 (en) * 2020-11-06 2025-11-20 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
JP7495340B2 (ja) * 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法
US12370196B2 (en) 2020-12-31 2025-07-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2022147155A1 (en) 2020-12-31 2022-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP7762444B2 (ja) * 2021-04-27 2025-10-30 アニマスキュア インコーポレイテッド． オキシカム系化合物を含む筋疾患の予防または治療用組成物
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3343295A (en) 1994-08-12 1996-03-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine salt
JP2896532B2 (ja) 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1999009988A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
IL159129A0 (en) * 2001-06-01 2004-05-12 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
GB0320382D0 (en) * 2003-08-30 2003-10-01 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Pharmaceutical compositions
JP2007505927A (ja) 2003-09-19 2007-03-15 ドラッグテック コーポレイション 薬物送達システム
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
WO2005105102A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
WO2007078874A2 (en) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
RU2470636C2 (ru) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
KR101767849B1 (ko) * 2007-06-20 2017-08-11 오스펙스 파마슈티칼스, 인코포레이티드 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
DK3100728T3 (da) * 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
WO2012054831A2 (en) * 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
CN102526058A (zh) * 2010-12-28 2012-07-04 秦引林 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物
WO2014161131A1 (en) * 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
KR102465027B1 (ko) * 2015-02-10 2022-11-09 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물

Also Published As

Publication number Publication date
ES2913288T3 (es) 2022-06-01
AU2020205306B2 (en) 2022-03-10
CN107405359A (zh) 2017-11-28
JP2023133545A (ja) 2023-09-22
IL281863B2 (en) 2025-04-01
JP7721602B2 (ja) 2025-08-12
KR20200117055A (ko) 2020-10-13
NZ742220A (en) 2023-07-28
CA3011562A1 (en) 2016-08-18
CA2976272A1 (en) 2016-08-18
IL253925A0 (en) 2017-10-31
EP3256138A2 (en) 2017-12-20
WO2016131067A3 (en) 2016-10-06
EP3256138A4 (en) 2019-10-02
MY191574A (en) 2022-06-30
KR20220110869A (ko) 2022-08-09
SI3256138T1 (sl) 2022-07-29
CA2976272C (en) 2018-09-04
KR20210111333A (ko) 2021-09-10
CY1125193T1 (el) 2024-12-13
AU2016218992C1 (en) 2019-09-26
AU2016218992A1 (en) 2017-08-17
JP2025142338A (ja) 2025-09-30
CN107405359B (zh) 2021-04-20
IL253925B (en) 2021-04-29
CA3204396A1 (en) 2016-08-18
EP4470614A2 (en) 2024-12-04
CA3011562C (en) 2023-08-29
AU2019203328B2 (en) 2020-05-28
JP7332202B2 (ja) 2023-08-23
SG11201706123XA (en) 2017-08-30
EP4470614A3 (en) 2025-03-05
PL3256138T3 (pl) 2022-08-01
DK3256138T3 (da) 2022-05-16
JP2019131596A (ja) 2019-08-08
AU2022203861A1 (en) 2022-06-23
AU2016218992B2 (en) 2019-02-14
EP4008319B1 (en) 2024-11-20
KR20170126915A (ko) 2017-11-20
AU2019203328C1 (en) 2020-08-27
KR102429352B1 (ko) 2022-08-03
KR102507663B1 (ko) 2023-03-07
KR20250099425A (ko) 2025-07-01
AU2019203328A1 (en) 2019-05-30
JP2022040370A (ja) 2022-03-10
KR20220153674A (ko) 2022-11-18
KR20220107313A (ko) 2022-08-02
KR102550497B1 (ko) 2023-07-03
CA3204396C (en) 2025-09-09
NZ734233A (en) 2018-05-25
HUE058677T2 (hu) 2022-09-28
WO2016131067A2 (en) 2016-08-18
KR102424013B1 (ko) 2022-07-25
MX380762B (es) 2025-03-12
IL316648A (en) 2024-12-01
AU2020205306C1 (en) 2022-10-13
JP2021066749A (ja) 2021-04-30
JP6842122B2 (ja) 2021-03-17
HK1243650A1 (zh) 2018-07-20
MX2021003230A (es) 2022-08-18
AU2020205306A1 (en) 2020-08-06
KR102827626B1 (ko) 2025-06-30
KR102465027B1 (ko) 2022-11-09
IL281863A (en) 2021-05-31
EP4008319A1 (en) 2022-06-08
KR102163404B1 (ko) 2020-10-08
PT3256138T (pt) 2022-05-23
EP3256138B1 (en) 2022-02-23
JP7017275B2 (ja) 2022-02-08
CN113144218A (zh) 2021-07-23
KR102447080B1 (ko) 2022-09-23
JP2018508570A (ja) 2018-03-29
IL281863B1 (en) 2024-12-01
AU2022203861B2 (en) 2024-09-19
LT3256138T (lt) 2022-06-10
SG10202010157VA (en) 2020-11-27
JP6746612B2 (ja) 2020-08-26
EP4008319C0 (en) 2024-11-20
RS63260B1 (sr) 2022-06-30
KR20230098923A (ko) 2023-07-04
KR20230038592A (ko) 2023-03-20
SMT202200194T1 (it) 2022-07-21

Similar Documents

Publication Publication Date Title
MX2017010304A (es) Composiciones farmaceuticas que comprenden meloxicam.
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
NI202000105A (es) Composiciones farmacéuticas que comprenden meloxicam
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CL2015001461A1 (es) Una formulación estabilizada de pemetrexed.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
DOP2015000006A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
BR112017014295A2 (pt) composição farmacêutica.
ECSP21006974A (es) Composiciones farmacéuticas que comprenden meloxicam
MY203481A (en) Pharmaceutical compositions comprising meloxicam
CL2018001236A1 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización
DOP2017000174A (es) Terapias de combinación para el tratamiento de cánceres
MX2017002700A (es) Composicion farmaceutica para el tratamiento de dolor agudo de dientes o de mandibula.
TH1501007612A (th) อมอร์ฟัสลีเทอร์โมเวียร์และสูตรผสมของแข็งทางเภสัชกรรมของมันสำหรับให้เข้าทางปาก
UY35541A (es) Composición de ácidos grasos omega-3, zinc y hierro para el tratamiento del trastorno por déficit de atención e hiperactividad (TDAH)
TH1601006737A (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค